Direct from Ann...
As in the paediatric study, the performance of the algorithm was evaluated using the method of leave-one-out cross-validation against the clinical diagnosis provided by the JHC clinical team. This diagnosis was based on the clinical presentations, auscultation findings (listening to the internal sounds of the body using a stethoscope) and imaging as well as laboratory test results when clinically indicated for the diagnosis of a given respiratory disease.
To suggest the good doctor has tainted his own trial with a lack of scientific objectivity, by using an approved method of study?? Wow..
The double blind method was for the FDA approval process.....
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Provides SMARTCOUGH-C May Study Update
Ann: ResApp Provides SMARTCOUGH-C May Study Update, page-112
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online